Trump’s $85 Billion Drug Price Cut Plan Faces Industry Backlash

President Donald Trump is reviving a controversial proposal to align U.S. prescription drug prices with those in other developed nations, a move that could slash domestic pharmaceutical spending by an estimated $85 billion over seven years. This initiative, known as the “Most Favored Nations” rule, aims to tie Medicare drug payments to the lower prices paid abroad. 

The pharmaceutical industry is sounding alarms, labeling the proposal as an “existential threat” that could stifle innovation and disrupt healthcare markets. Critics argue that implementing such a policy would face significant logistical challenges, including accounting for confidential discounts and potential pricing responses from pharmaceutical companies overseas. 

Despite these concerns, the Trump administration is pushing forward, with the Centers for Medicare and Medicaid Services expected to pilot the program through its innovation center. The plan builds on President Biden’s Inflation Reduction Act, which allows Medicare to negotiate drug prices but still results in substantially higher prices compared to other countries. 

As the debate intensifies, stakeholders across the healthcare spectrum are closely watching how this policy shift could reshape the pharmaceutical landscape in the United States.